Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
This Phase 2 clinical study delivers neurturin (NTN), a protein related to glial cell line-derived neurotrophic factor (GDNF), to both the putamen and substantia nigra. Patients are randomized to either the treatment versus sham surgery.
- Moderate to advanced Parkinson's disease
- Both sides affected, classic PD with motor fluctuations
- Good postural stability in the “on” state
- Age 35-70 years
- Normal cognitive status
For more information, please visit the study page at clinicaltrials.gov, here.